Mechanistic target of rapamycin (mTOR) is an important kinase that assimilates several 20 upstream signals including viral infection and facilitates appropriate response by the cell 21 through two unique complexes mTORC1 and mTORC2. Here, we demonstrate that 22 39 40 3
mTORC1 is activated early during HCV infection as antiviral response. Pharmacological 23 inhibition of mTORC1 promoted HCV replication as suggested by elevated levels of 24 HCV (+) and (-) RNA strands. This was accompanied by significant drop in extracellular 25 HCV RNA levels indicating defective post-replication stages. The increase in viral RNA 26 levels failed to augment intracellular infectious virion levels, suggesting that mTORC1 27 inhibition is detrimental to post-replication steps. Lower infectivity of the supernatant 28 confirmed this observation. Depletion of Raptor and ULK1 accurately reproduced these 29 results suggesting that mTORC1 imparted these effects on HCV through mTORC1-30 ULK1 arm. Interestingly, ULK1 depletion resulted in increased levels of miR-122, a 31 critical host factor for HCV replication, thus revealing a new mechanism of regulation by 32 ULK1. The binary effect of mTORC1 on HCV replication and egress suggests that 33 mTORC1-ULK1 could be critical in replication: egress balance. Interestingly we discover 34 that ULK1 depletion did not interfere with autophagy in Huh7.5 cells and hence the 35 effects on HCV replication and post-replication events are not resultant of involvement 36 of autophagy. Our studies demonstrate an overall ULK1 mediated anti-HCV function of 37 mTORC1 and identifies an ULK1-independent autophagy that allows HCV replication in 38 spite of mTORC1 activation.
INTRODUCTION 43 Hepatitis C Virus (HCV) is the major cause of hepatocellular carcinoma worldwide 44 (Choo et al., 1989) . It is the lone member of Hepacivirus genus under Flaviviridae family 45 and is represented by seven genotypes. HCV spreads through blood or organs and 46 over 170 million people are estimated to have been infected by this pathogen (Hadigan 47 and Kottilil, 2011), of which over 71 million people worldwide are chronically infected. 48 Conventional combination therapy using pegylated IFN-α and Ribavirin is associated 49 with inconsistent results and causes severe side effects (Fried, 2002 Takeda et al., 2017) . Therefore, there is the need for continued efforts for evolving 54 therapeutic regimens to counter the HCV menace. 55 Of the several host factors critical for HCV sustenance, miR-122, a liver enriched 56 miRNA, is indispensable for HCV replication (Jopling et al., 2005) . miR-122 is a unique 57 case of miRNA mediated positive regulation, where it binds to the 5' UTR of HCV and 58 stabilizes it (Shimakami et al., 2012) . More recent studies suggest that miR-122 does 59 more than providing stability, but is involved in HCV RNA synthesis (Li et al., 2013) . 60 Other studies also indicate that miR-122 regulates HCV replication: translation balance 61 (Masaki et al., 2015) . It has been demonstrated that simple expression of miR-122 62 renders otherwise non-permissive hepatic cell lines HCV permissive (Kambara et al., 63 2012). 64 Mechanistic target of Rapamycin (mTOR), a major serine/threonine kinase found in 65 eukaryotes is the target of the versatile drug Rapamycin (Brown et al., 1994; Sabatini et 66 al., 1994) . mTOR functions as the catalytic subunit of at least two distinct complexes, 67 mTORC1 and mTORC2 (Saxton and Sabatini, 2017) . mTORC1 is constituted by 68 Raptor, mLST8, PRAS40 and DEPTOR in addition to mTOR (Kim et al., 2002;  69 Wullschleger et al., 2006) . mTORC1 is a major signaling hub that regulates several 70 cellular and metabolic activities such as protein translation, autophagy, lipid and nucleic 71 acid biosynthesis. Deregulated mTORC1 signaling is implicated in several cancers 72 (Hsieh et al., 2010; Laplante and Sabatini, 2012) . mTORC1 kinase regulates cell 73 functioning by phosphorylating its diverse set of substrates. Of these, eukaryotic 74 translation initiation factor E (eIF4E)-binding protein (4EBP1) is a major substrate that 75 regulates translation initiation (Haghighat et al., 1995) . 4EBP1, in its 76 hypophosphorylated form sequesters eukaryotic cap binding protein eIF4E thereby 77 inhibiting cap dependent translation (Richter and Sonenberg, 2005 infection. In the present study, we sought to understand the role of mTOR in HCV life 116 cycle and identified that activation of mTORC1 by HCV early during infection is an 117 antiviral response by the cells. We identify that mTORC1 restricts HCV replication 118 through ULK1 that further executes the regulation through modulating the levels of miR- 167 In previous experiments, the role of mTOR was addressed well beyond the peak HCV Figure 5C ). On the 238 contrary, depletion of Rictor, an integral mTORC2 component, had no effect on HCV 239 replication ( Figure S5A and S5B) . These results confirm that mTOR restricts HCV 240 replication and promotes viral release through mTORC1 but not mTORC2. Figure S6A and S6B) , did not alter HCV replication in Huh7.5 cells, suggesting its 245 dispensability in HCV replication. Next, we analyzed HCV replication in ULK1 depleted 246 Huh7.5 cells. Interestingly, robust ULK1 depletion ( Figure 5D ) caused significant 247 increase of intracellular ( Figure 5E ) and severe drop of supernatant HCV RNA levels 248 ( Figure 5F ), consistent with mTOR inhibition and Raptor depletion. Taken together, 249 these results demonstrate that mTORC1 restricts HCV replication through a mechanism 250 that involves ULK1, but not 4EBP1. Figure 6C ).
Low mTOR activity at the time of infection enhances HCV replication
These observations suggest that mTORC1 regulates miR-122 levels 261 through ULK1. These data also suggest that ULK1 has an unidentified role of regulating 262 miR-122 levels through which HCV replication is regulated. These results propose that 263 mTORC1, through ULK1, inhibits miR-122 levels. To the best of our knowledge, this 264 mechanism of regulation of HCV replication is hitherto unidentified. Technologies. Oligo details are provided in Table S1 . 439 Immunobloting 440 Immunobloting was performed as described earlier (George et al., 2012) . Densitometric 441 analyses of blots were done by using Image J software. Relative phosphorylations were 442 calculated from the ratios of any phosphorylated band to its total protein that was 443 normalized to the corresponding β-Tubulin as loading control (P/T/C).
444
Polysome analysis 445 Polysome profiles of HCV infected cells undergone pre-treatment were prepared as 446 described elsewhere (George et al., 2012 
